JP2005535328A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535328A5
JP2005535328A5 JP2004527772A JP2004527772A JP2005535328A5 JP 2005535328 A5 JP2005535328 A5 JP 2005535328A5 JP 2004527772 A JP2004527772 A JP 2004527772A JP 2004527772 A JP2004527772 A JP 2004527772A JP 2005535328 A5 JP2005535328 A5 JP 2005535328A5
Authority
JP
Japan
Prior art keywords
cells
multiple sclerosis
nos
seq
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004527772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535328A (ja
JP4705371B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/024548 external-priority patent/WO2004015070A2/en
Publication of JP2005535328A publication Critical patent/JP2005535328A/ja
Publication of JP2005535328A5 publication Critical patent/JP2005535328A5/ja
Application granted granted Critical
Publication of JP4705371B2 publication Critical patent/JP4705371B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004527772A 2002-08-08 2003-08-06 Ｔ細胞の単離および同定 Expired - Fee Related JP4705371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40252102P 2002-08-08 2002-08-08
US60/402,521 2002-08-08
PCT/US2003/024548 WO2004015070A2 (en) 2002-08-08 2003-08-06 Isolation and identification of t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010098263A Division JP2010178759A (ja) 2002-08-08 2010-04-21 Ｔ細胞の単離および同定

Publications (3)

Publication Number Publication Date
JP2005535328A JP2005535328A (ja) 2005-11-24
JP2005535328A5 true JP2005535328A5 (https=) 2006-09-14
JP4705371B2 JP4705371B2 (ja) 2011-06-22

Family

ID=31715870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004527772A Expired - Fee Related JP4705371B2 (ja) 2002-08-08 2003-08-06 Ｔ細胞の単離および同定
JP2010098263A Pending JP2010178759A (ja) 2002-08-08 2010-04-21 Ｔ細胞の単離および同定

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010098263A Pending JP2010178759A (ja) 2002-08-08 2010-04-21 Ｔ細胞の単離および同定

Country Status (18)

Country Link
US (2) US7695713B2 (https=)
EP (2) EP1546719B1 (https=)
JP (2) JP4705371B2 (https=)
KR (1) KR100795840B1 (https=)
CN (1) CN100567987C (https=)
AU (1) AU2003258090B2 (https=)
BR (1) BRPI0305769A8 (https=)
CA (2) CA2492848C (https=)
ES (2) ES2537951T3 (https=)
IL (1) IL166332A (https=)
MX (1) MXPA05001044A (https=)
NO (2) NO338881B1 (https=)
NZ (1) NZ537816A (https=)
PL (1) PL214283B1 (https=)
PT (2) PT1546719E (https=)
RU (1) RU2327487C2 (https=)
WO (1) WO2004015070A2 (https=)
ZA (1) ZA200500985B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
PL1989544T3 (pl) * 2006-03-02 2012-01-31 Antitope Ltd Testy na komórkach T
ES2686593T3 (es) 2006-05-31 2018-10-18 The Regents Of The University Of California Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
GB0707933D0 (en) * 2007-04-24 2007-05-30 Apitope Technology Bristol Ltd Disease markers
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
AU2009316371B2 (en) * 2008-11-21 2014-02-20 University Of Miami HIV/SIV vaccines for the generation of mucosal and systemic immunity
US8497071B2 (en) 2009-06-29 2013-07-30 California Institute Of Technology Isolation of unknown rearranged T-cell receptors from single cells
WO2011080349A1 (en) * 2010-01-04 2011-07-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease
WO2011106558A1 (en) * 2010-02-24 2011-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for autoimmune disease diagnosis, prognosis, and treatment
DE102011050550A1 (de) * 2011-05-20 2012-11-22 Wolfgang Göhde Verfahren und Anordnung zur Quantifizierung von Untergruppen aus einer Mischpopulation von Zellen
BR112013033988B1 (pt) 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
CN109254143A (zh) * 2011-09-28 2019-01-22 艾瑞普特公司 使用Arm-PCR和高通量测序鉴定抗原特异的适应性免疫应答
FR2992427A1 (fr) * 2012-06-20 2013-12-27 Assist Publ Hopitaux De Paris Methode de pronostic d'un lymphome et kit pour sa mise en oeuvre
JP6464081B2 (ja) * 2012-06-27 2019-02-06 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー フローサイトメトリーを用いたｒｎａ測定によるｔ細胞活性化のための迅速アッセイ
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
JP6508873B2 (ja) * 2014-01-20 2019-05-08 国立大学法人富山大学 抗原特異的ｔ細胞受容体の取得方法
WO2017040594A1 (en) 2015-08-31 2017-03-09 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset alzheimer's disease
ES2897974T3 (es) * 2015-09-11 2022-03-03 Astellas Pharma Inc Método para producir células progenitoras renales
WO2017203356A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
MX2019000180A (es) * 2016-06-28 2019-11-05 Geneius Biotechnology Inc Composiciones de células t para la inmunoterapia.
RU2769474C2 (ru) * 2017-01-20 2022-04-01 Атара Байотерапьютикс, Инк. Способы лечения рассеянного склероза с использованием аутологичных т-клеток
WO2018231151A1 (en) 2017-06-14 2018-12-20 Singapore Health Services Pte. Ltd. Methods and kits for evaluating clinical outcomes of autoimmune disease
US20210061875A1 (en) 2017-12-29 2021-03-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Compositions and methods for treating autoimmune disease
PL445027A1 (pl) * 2023-05-29 2024-12-02 Uniwersytet Medyczny w Łodzi Sposób diagnozowania stwardnienia rozsianego in vitro

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US4902857A (en) * 1988-12-27 1990-02-20 American Telephone And Telegraph Company, At&T Bell Laboratories Polymer interconnect structure
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
WO1992001044A1 (en) 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
EP0688223A4 (en) * 1993-03-12 1998-05-13 Cellcor Inc -i (IN VITRO) 'ASSAY' FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
AU6376194A (en) 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5956058A (en) * 1993-11-05 1999-09-21 Seiko Epson Corporation Ink jet print head with improved spacer made from silicon single-crystal substrate
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5723503A (en) 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US6033661A (en) * 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US6096314A (en) * 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
WO2000000828A1 (en) * 1998-06-26 2000-01-06 Biomira Inc. Method of detecting t-cell activation
AU5906099A (en) 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
DE60045188D1 (de) * 1999-02-23 2010-12-16 Baylor College Medicine T-ZELLREZEPTOR Vb-Db-Jb-SEQUENZ UND VERFAHREN FÜR IHREN NACHWEIS
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
WO2002016434A1 (en) 2000-08-22 2002-02-28 Baylor College Of Medicine T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1444330A1 (en) * 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US20050181459A1 (en) * 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells

Similar Documents

Publication Publication Date Title
JP2005535328A5 (https=)
Nishimura et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development
Barbic et al. Role of gamma interferon in natural clearance of Bordetella pertussis infection
Havell Evidence that tumor necrosis factor has an important role in antibacterial resistance.
KÖHLER et al. Intrafamilial levels of Streptococcus mutans and some aspects of the bacterial transmission
Ha et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis
Sharquie BCG is a good immunotherapeutic agent for viral and autoimmune diseases: is it a new weapon against coronavirus (COVID-19)?
JP2007515393A5 (https=)
Elzein et al. Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature
Ma et al. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre-and post-exposure infections by driving Th1-type T cell immunity
KR970702057A (ko) 면역치료제 및 이의 용도(immunotherapeutic agent and its use)
Li et al. Memory T cells in flavivirus vaccination
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
Ismail et al. Relative importance of T-cell subsets in monocytotropic ehrlichiosis: a novel effector mechanism involved in Ehrlichia-induced immunopathology in murine ehrlichiosis
Moyat et al. Role of inflammatory monocytes in vaccine-induced reduction of Helicobacter felis infection
US20030108543A1 (en) Photophoretic auto immune stimulation
Goodman et al. An improved primary response from mouse spleen cells cultured in vivo in diffusion chambers
Marshall et al. Production of tumor necrosis factor and nitric oxide by macrophages infected with live and dead mycobacteria and their suppression by an interleukin-10-secreting recombinant
Taweechaisupapong et al. Langerhans cell density and serological changes following intradermal immunisation of mice with dengue 2 virus
JP2007509063A5 (https=)
Talwar et al. Launching of immunization with the vaccine Mycobacterium indicus pranii for eradication of leprosy in India
Chung et al. Albert Léon Charles Calmette (1863-1933) and the antituberculous BCG vaccination
Das Oxy radicals and their clinical implications
TWI295688B (en) A method for inhibition of enterovirus and/or influenza virus reproduction by allophycocyanin in vitro
Halliday et al. A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine